CD44 and prostate carcinoma: In the subsequent step, Western Blot analyses confirmed the expression of the target proteins CD44 and EpCAM in the prostate cancer cell line PC3-PSMA and the prostate cancer stem cell-like (PCSC-like) cell line PC3-MM2, whereas the control cell line CHO showed no expression of either antigen (Figure 2a).